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Abstract
Selected for its high relative abundance, a protein spot of MW 75 kDa, pI 5.5 was cored from a Coomassie-stained two-dimensional
gel of proteins from 2850 zona-free metaphase II mouse eggs and analyzed by tandem mass spectrometry (TMS), and novel microsequences
were identified that indicated a previously uncharacterized egg protein. A 2.4-kb cDNA was then amplified from a mouse ovarian
adapter-ligated cDNA library by RACE-PCR, and a unique 2043-bp open reading frame was defined encoding a 681-amino-acid protein.
Comparison of the deduced amino acid sequence with the nonredundant database demonstrated that the protein was 40% identical to the
calcium-dependent peptidylarginine deiminase (PAD) enzyme family. Northern blotting, RT-PCR, and in situ hybridization analyses
indicated that the protein was abundantly expressed in the ovary, weakly expressed in the testis, and absent from other tissues. Based on
the homology with PADs and its oocyte-abundant expression pattern, the protein was designated ePAD, for egg and embryo-abundant
peptidylarginine deiminase-like protein. Anti-recombinant ePAD monospecific antibodies localized the molecule to the cytoplasm of
oocytes in primordial, primary, secondary, and Graafian follicles in ovarian sections, while no other ovarian cell type was stained. ePAD
was also expressed in the immature oocyte, mature egg, and through the blastocyst stage of embryonic development, where expression levels
began to decrease. Immunoelectron microscopy localized ePAD to egg cytoplasmic sheets, a unique keratin-containing intermediate filament
structure found only in mammalian eggs and in early embryos, and known to undergo reorganization at critical stages of development.
Previous reports that PAD-mediated deimination of epithelial cell keratin results in cytoskeletal remodeling suggest a possible role for ePAD
in cytoskeletal reorganization in the egg and early embryo.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
During growth, the oocyte accumulates a pool of mater-
nal gene products and organelles required for early devel-
opment. In the fully grown egg, the transcriptional machin-
ery is silent and, once ovulated, the terminally differentiated
egg will die if it does not bind and fuse with a sperm. If
fertilization occurs, however, maternal gene products or-
chestrate the transformation of the egg into a totipotent
zygote within several hours. Following gamete fusion, cal-
cium transients propagated in the egg cytoplasm lead to the
activation of signal transduction cascades, which are
thought to mediate early embryonic events, such as remod-
eling of the cortical cytoskeleton, cortical granule exocyto-
sis, completion of meiosis, polar body emission, and for-
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mation of the male and female pronuclei (Yanagimachi,
1994). Reprogramming of the parental chromatin is also
thought to occur soon after fertilization, and by the two-cell
stage, maternal transcripts begin to be replaced by embry-
onic transcripts, and the embryonic genome is activated
(Schultz et al., 1999). Maternal factors, however, continue
to persist in the early embryo until at least the morula stage
of development (Pratt et al., 1983).
Many of the structural and molecular mechanisms me-
diating the physiological changes in the early embryo are as
yet incompletely characterized. One of the most abundant
cytoskeletal components of the mammalian egg is a fibrous
network of intermediate filaments (Gallicano et al., 1994a;
Lehtonen, 1985, 1987; Lehtonen et al., 1983; Uranga et al.,
1995) named the cytoplasmic sheets (Capco et al., 1993).
These organelles were previously thought to be either yolk
platelets or possibly ribosome storage sites (Yanagimachi,
1994); however, electron microscopic studies indicate that
the highly ordered sheets are composed of parallel arrays of
10-nm fibers (Gallicano et al., 1991). This filamentous
network is stabilized by cross-bridges and is overlain with a
tightly packed particulate material. Solubility and immuno-
logical studies indicate that the Tween 20 insoluble cross-
linked fibers contain keratin (but not vimentin or tubulin)
and the soluble fraction largely consists of an unidentified
69-kDa protein (Capco et al., 1993). Soluble protein ki-
nase C associates with the cytoplasmic sheets, phosphory-
lates cytokeratin and the 69-kDa soluble protein, and may
be responsible for initiating the changes in spatial organi-
zation that these sheets undergo at the time of fertilization
(Gallicano and Capco, 1995). Cytoplasmic sheets arise dur-
ing oocyte development (Gallicano et al., 1994b), are
unique to the egg and early embryo, are conserved among
mammals (Gallicano et al., 1992), and undergo extensive
spatial reorganizations during the critical developmental
transitions of fertilization, compaction, and blastulation
(Capco and McGaughey, 1986).
Peptidylarginine deiminases (PADs) are a family of cal-
cium-dependent sulfhydryl enzymes that convert arginine
residues to citrulline in proteins (Senshu, 1990). PAD ac-
tivity appears to be upregulated by a variety of estrogenic
compounds (Nagata et al., 1990; Senshu et al., 1989; Taka-
hara et al., 1992), and to date, four types of PADs have been
characterized with each differing in its pattern of substrate
specificity and tissue distribution. For example, the widely
distributed and well characterized type II PAD is especially
abundant in muscle (Takahara et al., 1983, 1986) and brain
(Akiyama et al., 1999; Asaga and Ishigami, 2001) and is
associated with deimination of myelin basic protein (La-
mensa and Moscarello, 1993; Moscarello et al., 2002). PAD
V, found in granulocyte-differentiated HL-60 cells, is
thought to play a role in myeloid cell differentiation (Na-
kashima et al., 1999), and likely targets nucleophosmin and
histone core proteins for deimination (Hagiwara et al.,
2002). Type I and III PADs have been characterized in the
epidermis; with type III PAD being found to deiminate
trichohyalin in hair follicles (Kanno et al., 2000; Nishijyo et
al., 1997) and Type I PAD deiminating keratin and filaggrin
during epidermal differentiation (Akiyama and Senshu,
1999; Senshu et al., 1999a). It is thought that the deimina-
tion of keratin and filaggrin in the epidermis induces
changes in the spatial organization of keratin intermediate
filaments during keratinocyte maturation (Ishida-Yamamoto
et al., 2002). Deiminated keratin has been identified in day
18 embryos (Akiyama and Senshu, 1999); however, the
presence of deiminated keratin at earlier stages of develop-
ment has not been investigated.
In an ongoing project to identify previously uncharacter-
ized proteins in the ovulated mouse egg, we have been
performing tandem mass spectroscopic analysis of abundant
oocyte proteins that have been cored from Coomassie-
stained two-dimensional (2D) gels. One dominant egg pro-
tein spot that yielded novel peptide microsequences was
cloned and the cDNA characterized. Using Northern blot-
ting, the tissue distribution was determined and the protein
was found to be expressed in primary oocytes and to persist
until at least the blastocyst stage of development. Due to its
40% identity with the peptidylarginine deiminase enzyme
family, the name ePAD, for egg and embryo abundant PAD,
was selected. Remarkably, at the ultrastructural level, ePAD
localized to the egg’s cytoplasmic sheets, a cytoskeletal
structure unique to the egg and early embryo. The discovery
that ePAD is associated with the egg cytoplasmic sheets
leads to the hypothesis that arginine deiminase reactions
directed against cytokeratin, and possibly other proteins,
results in reorganization of the cytoskeleton during early
development.
Materials and methods
Two-dimensional electrophoresis
Mouse oocytes (2850 for the Coomassie-stained gel in
Fig. 1 and 300 per blot in Fig. 6) were collected and
dezonulated as described previously (Coonrod et al., 1999).
The zona-free eggs were then washed six times in PBS
containing 10 g/ml polyvinylalcohol (PVA; Sigma) and
extracted in Celis lysis buffer [containing 2% (v:v) NP-40,
9.8 M urea, 100 mM dithiothreitol (DTT), 2% ampholines
(pH 3.5–10), and protease inhibitors] for 30 min at room
temperature (Rasmussen et al., 1991). Isoelectric focusing
(IEF) was performed by using the BioRad Protean II Multi-
Cell apparatus with an ampholine mixture (Pharmacia Bio-
tech, Uppsala, Sweden) of pH 3.5–5 (30%), 3.5–10 (40%),
5–7 (20%), and 7–9 (10%). The tube gels were placed on
12% slab gels (16  16 cm, plates 1.5 mm diameter), and
the focused proteins were separated in the second dimen-
sion. The gels were then either stained with Coomassie or
electroblotted to nitrocellulose membranes. For Coomassie
staining, the gels were fixed overnight in a solution of 50%
ethanol and 10% acetic acid and placed in a solution con-
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taining 0.1% Coomassie R250, 40% methanol, and 0.1%
acetic acid for 4 h. The gels were then destained in a
solution of 10% acetic acid and 50% methanol.
Tandem mass spectroscopic analysis of egg peptides
Two 75-kDa (pI 5.5) Coomassie-stained protein spots
were cored from the 2D SDS-PAGE gel, fragmented,
destained in methanol, reduced in 10 mM dithiothreitol, and
alkylated in 50 mM iodoacetamide in 0.1 M ammonium
bicarbonate. The gel pieces were then incubated with 12.5
ng/ml trypsin in 50 mM ammonium bicarbonate overnight
at 37°C. Peptides were extracted from the gel pieces in 50%
acetonitrile and 5% formic acid and microsequenced by
tandem mass spectrometry at the Biomolecular Research
Facility of the University of Virginia.
Adapter-ligated cDNA library construction and RACE-
PCR cloning of ePAD cDNA
Two micrograms of mouse ovarian poly(A) mRNA,
isolated using the FastTrack 2.0 kit from Invitrogen (Carls-
bad, CA), was used as the template for the construction of
a Marathon adaptor ligated cDNA library (Clontech, Palo
Alto, CA). Oligo(dT) primers, as well as avian myeloblas-
tosis virus (AMV) reverse transcriptase, were used to con-
struct the first strand of cDNA. The RNA was digested and
the second strand of cDNA was synthesized in a simulta-
neous reaction with a mixture of Escherichia coli DNA
polymerase I, Rnase H, and E. coli DNA ligase. The cDNA
ends were then blunted by using T4 DNA polymerase, and
Marathon cDNA adaptors were ligated to both ends of the
cDNA by the addition of T4 DNA ligase.
RACE PCRs were performed using the Amplitaq Gold
DNA polymerase from Perkin-Elmer (Norwalk, CT) with
ovarian library cDNA templates. Cycling parameters were:
94°C, 10 min; 94°C, 15 s; 60°C, 30 s; 72°C, 2 min; and
72°C, 10 min, for 40 cycles. PCR of plasmid templates was
performed under the same conditions, except that Promega
Advantage 2 taq polymerase was used. The primers for
cloning the full-length ORF of ePAD into the TOPO clon-
ing vector (Invitrogen) were 5-GTACTCGAGATGGTAG-
GCATGGAAATCACC-3 and 5-CGATCTAGAT-
GGGGTCATCTTCCACCACTT-3, and the AP1 primer
supplied in the Marathon ready cDNA kit (Clontech).
Northern blot analysis
A randomly primed probe was generated corresponding
to the 1100-bp N-terminal region of ePAD by using the
Prime-a-Gene Labeling System (Promega, Madison, WI).
Twenty-five nanograms of cDNA were denatured at 95°C
for 5 min. After cooling on ice for 5 min, 50 mM Tris–HCl,
pH 8.0, 5 mM MgCl2, 2 mM DTT, 200 mM Hepes, pH 6.6,
random hexadeoxyribonucleotides, 400 g/ml of BSA, 333
nM [-32P]dCTP, 20 M each of dATP, dGTP, and dTTP,
and 5 units of DNA polymerase I, large (Klenow) fragment,
were added to the cDNA. This was incubated for 2 h at
22°C, and subsequently passed through a NucTrap (Strat-
agene, La Jolla, CA) column to remove unincorporated
nucleotides from the probe. A mouse multi-tissue Northern
blot (Clontech) was incubated with ExpressHyb hybridiza-
tion solution (Clontech) for 1 h at 65°C. The probe was
heated to 95°C for 5 min, and placed in 10 ml of fresh
ExpressHyb. This was incubated with the blot overnight at
55°C, and washed on the following day, twice for 15 min
with 2 SSC and 0.5% SDS, twice for 30 min in 0.1 SSC
and 0.5% SDS at 65°C. Signals were detected by exposure
to X-ray film for 24 h and for 10 days.
RT-PCR of ePAD in mouse tissues
The Mouse Multiple Tissue cDNA Panel from Clontech,
comprised of cDNA from 11 different tissues, served as
template in the PCRs. cDNAs from the Panel were used to
amplify ePAD and control G3PDH cDNA fragments in
50–l reactions (10 mM Tris–HCl, 1.5 mM MgCl2, 50 mM
KCl, 0.1% Triton X-100, 0.2 mM of each dNTP, 0.5 U of
Taq polymerase, and 0.5 mM of each primer). Thermocy-
cler settings consisted of a 10-min incubation at 95°C,
followed by 40 cycles at 95°C (15 s), 60°C (30 s), and 72°C
(2 min). Extension progressed for 10 min at 72°C. Ten
percent of product was later analyzed on 1.5% agarose gels
and confirmed by Southern blotting. The following ePAD
primers were used: 1–27, 5-GGTAAGGACTGCTGA-
CAGTGGC-TAGCT-3; 2222–2249, 5-CCTCCAGAAG-
TGTCAAGCTGGTAGATGT-3. G3PDH primers were in-
cluded in the previously mentioned Clontech kit.
In situ hybridization
Ovaries from fertile ICR female mice were fixed in
neutral buffered formalin solution (4%) (Sigma, St. Louis,
MO) for 12 h. Following dehydration, the blocks were
embedded in paraffin, sectioned (2.5 mm), and mounted on
positively charged slides. To prepare a riboprobe, a DNA
fragment consisting of the 5 250 nucleotides of the ePAD
ORF was subcloned into the pBluescript SK plasmid vector
and used as template for in vitro transcription (Angerer et
al., 1987). Tritiated Q2 uridine triphosphate (UTP) was
incorporated into the riboprobes by either T3 (sense) or T7
(antisense) RNA polymerase. A labeled -actin riboprobe
was used as a positive control. The sections were deparaf-
finized, rehydrated, and treated with proteinase K. The in
situ hybridization solution contained 50% formamide, 0.3
M NaCl, 20 mM Tris–HCl, 1 mM EDTA (pH 8.0), Den-
hardt’s solution, 500 mg/ml yeast tRNA, and 10% dextran
sulfate. The final probe concentration was normalized for
probe length and applied at full saturation (0.2 mg/ml/kb
complexity). The hybridization was carried out at 55–65°C.
After hybridization, the sections were washed under high-
stringency conditions to remove nonspecific hybridization.
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The slides were overlaid with autoradiograhy emulsion,
exposed 2–4 weeks at 48°C, developed photographically,
and lightly stained with hematoxylin and eosin. Dark field
images were then captured at 200 by using a Zeiss mi-
croscope.
Expression of recombinant protein and antibody
production
Primers were designed to generate a PCR product en-
coding amino acids 1–200 of the open reading frame. The
sense primer, 5-TAAGGATCCGATGGTAGGCATGGA-
AATCACCTTGG-3, contained an engineered BamHI re-
striction site, while the anti-sense primer, 5-GTACTC-
GAGCCAGCCTCTCTGAGACCAGTAGACTCT-3, had
a XhoI restriction site. The primers were used to amplify the
cDNA fragment, and the PCR product was cloned into the
BamHI–XhoI sites of the pET22b expression vector (Nova-
gen, Madison, WI). Once the construct was verified, it was
transformed into E. coli strain BL21 DE3 cells (Stratagene).
A single positive colony was used to inoculate a 10-L
culture that was grown at 37°C in Luria broth (LB), in the
presence of 50 mg/mL ampicillin until the A600 reached
0.6. Recombinant protein expression was induced with 1.0
mM isopropyl-1-thio--D-galactopyranoside (IPTG) for 3 h.
Protein was purified from the cells by Ni-affinity chroma-
tography, which binds to a 6 His tag attached to the
recombinant protein (Reddi et al., 1994). Half of the bio-
mass was suspended in 5 mM imidazole, 0.5 M NaCl, and
20 mM Tris–HCl, pH 7.9, and was sonicated four times for
45 s. The sonicated extract was centrifuged at 20,000g for
15 min to collect inclusion bodies and cellular debris. The
supernatant was removed, and the pellet was then resus-
pended in 6 M urea, 5 mM imidazole, 0.5 M NaCl, and 20
mM Tris–HCl, pH 7.9. This was incubated on ice for 1 h to
completely dissolve the protein. The remaining insoluble
material was removed by centrifugation at 39,000g for 20
min and filtration through a 0.45-micron membrane. The
remaining supernatant was bound overnight at 4°C to nickel
charged by His-Bind Resin (Novagen) while shaking
gently. After centrifugation, the resin was washed twice for
20 min with 5 mM imidazole, 0.5 M NaCl, and 20 mM
Tris–HCl, pH 7.9, and once with 20 mM imidazole, 0.5 M
NaCl, and 20 mM Tris–HCl, pH 7.9, for 20 min. The
product was eluted with 1 M imidazole, 0.5 M NaCl, and 20
mM Tris–HCl, pH 7.9, for 20 min and collected. Elute from
the column was passed through a PREP cell (BioRad), in
order to remove remaining contaminants. Final product was
then dialyzed against 1.0 mM ammonium bicarbinate for
36 h before lyophilization and reconstitution.
Polyclonal antibody production and IgG purification
Three adult male Hartley guinea pigs (albino retired
breeders) were used for antibody production against a par-
tial fragment (extreme 200 N-terminal amino acids) en-
coded in the pET22b/ePAD clone. Preimmune serum was
collected by heart puncture, and subsequently, each animal
was injected with 100 g of purified recombinant PAD
(rePAD) in an emulsion with Freund’s complete adjuvant.
Each animal received two booster immunizations with 50
g of purified rePAD in Freund’s incomplete adjuvant at
3-week intervals. For all immunizations, half of the antigen
emulsion was injected intramuscularly in the leg and half
subcutaneously in three sites on the back. All animals were
then exsanginated by heart puncture 10 days after the final
immunization, and the blood was collected in serum sepa-
ration tubes (Becton Dickinson, Franklin Lakes, NJ). After
centrifugation at 1750g for 10 min, the serum was removed
and frozen until needed. A prepacked Protein A column
from Pierce was used for purifying IgGs from anti-rePAD
mouse serum. The column was prewashed with 5 mL of
sterile water. To calibrate the column, 5 mL of binding
buffer supplied by Pierce was then added and allowed to
drain. Sera was diluted 1:10 with binding buffer, passed
though the column in 4-mL increments, and the bound resin
was washed with binding buffer. IgGs were eluted from the
column with elution buffer from Pierce and dialyzed against
PBS before quantitating.
Fig. 1. Location of ePAD on a Coomassie-stained 2D electrophoretic gel of
2850 NP-40 extracted zona-free mouse oocytes. Arrows indicate the two
protein spots that were cored from the gel for TMS analysis. The putative
ePAD protein chain is delineated by the brackets.
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Anti-ePAD antibody specificity and ePAD solubility
characteristics
BL21 cells expressing rePAD were sonicated and 20 g
bacterial protein, 50 oocytes, and one million sperm per lane
were solubilized in Laemmli buffer (Laemmli, 1970) and
heat denatured at 95°C. The samples were then loaded onto
a 12.5% linear gel, and separated at 100 V for 3 h. Proteins
then electrotransferred onto 0.2 m nitrocellulose (Bio-Rad
Laboratories, Hercules, CA) for 40 min at 100 V for West-
ern blotting.
To investigate solubility characteristics, 70 mouse eggs
were extracted with NP-40 lysis buffer (150 mM sodium
chloride, 1.0% NP-40, and 50 mM Tris, pH 8.0), incubated
on ice for 30 min, and passed through a 25-G needle three
times. The extract was then centrifuged for ten minutes at
10,000g. The supernatant and pellet were each solubilized
in Laemmlie buffer, heat denatured at 95°C, and separated
on a 12.5% SDS-PAGE gel under reducing and nonreduc-
ing (lacking -mercaptoethanol) conditions. Protein was
then transferred onto a nitrocellulose and blotted as de-
scribed below.
Western blot analysis
For Western blot analysis of ovarian ePAD expression,
ovaries from 2, 4, 8, 15 wk, and retired breeder females
were homogenized in extraction buffer (PBS, 1% NP-40,
and 1 concentration of Complete, EDTA-free Protease
Inhibitor Cocktail Table; Roche, Mannheim, Germany). Af-
ter homogenization, the samples were sonicated for 30 s
each and quantified using the Biorad DC Protein Assay kit
(Biorad). Equal amounts of each sample (21.5 g) were
loaded on a 12.5% SDS-PAGE gel, and separated at 115 V.
Protein was then blotted to nitrocellulose, and stained with
Ponceu.
All blots were blocked with 5% nonfat dry milk in PBS
with 0.05% Tween 20 (PBS-T) for 30 min, washed and
incubated with a 1:5000 dilution of anti-rePAD guinea pig
sera. The blots were then washed two times for 10 min in
PBS-T, and incubated with a 1:10,000 dilution of peroxi-
dase conjugated goat anti-guinea pig IgG (Jackson Immu-
noResearch, West Grove, PA) secondary antibody for 1 h
and washed two times for 10 min in PBS-T. The blots were
then either developed in TMB peroxidase substrate (3,3,
5,5-tetramethylbenzidine; Kirkegaard and Perry Laborato-
ries, Gaithersburg, MD) or with ECL reagent (Amersham
Corp., Buckinghamshire, UK) and developed as described
previously (Coonrod et al., 1999).
Indirect immunofluorescence of ovarian sections, ovaries,
and embryos
Cryosections (5 m) of mouse ovary were processed for
indirect immunofluorescence. Slides were immersed in 95%
ethanol for 10 min, washed, and incubated in a blocking
buffer of PBS which contained 3% BSA and a 1:50 dilution
of normal goat serum for 20 min at room temperature. Next,
the slides were incubated with blocking buffer which con-
tained either a 40-g/ml ePAD IgG or preimmune IgG for
1 h at room temperature, washed, incubated in blocking
Fig. 2. Complementary DNA and deduced amino acid sequence of ePAD.
The untranslated flanking regions are shown in lower case letters. Peptide
sequences originally obtained by mass spectrometry are underlined.
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buffer containing goat anti-guinea pig IgG-FITC (1:200
dilution), washed again, and the slides were coverslipped
and stored at 4°C prior to imaging. All oocytes and embryos
were obtained from ICR 25–30 g females (Hilltop Labs).
Germinal vesicle oocytes and metaphase II eggs were ob-
tained as previously described (Coonrod et al., 1999, 2001).
Fig. 3. Amino acid sequence comparison of ePAD with the four known mouse peptidylarginine deiminases (PADs). The sequences were aligned by using
the ClustalW alignment program in BioEdit sequence alignment editor. Identical residues are shown in black boxes, and conserved residues are shown in
gray boxes. Dashes indicate gaps inserted to maximize sequence alignment. PAD Accession Nos. are as follows: type I, NP_035198; type II, NP_032838;
type III, NP_035190 type IV, NP_035191; ePAD, NP_694746. PADs I–IV are approximately 50% identical to each other, while ePAD is approximately 40%
identical to known murine PADs.
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Pronuclear embryos were obtained from females after in-
jection of 10 I.U. of PMSG followed 48 h later by 10 I.U.
of hcG and mating with ICR male retired breeders. Eighteen
to twenty-four hours after injection of hCG, pronuclear
staged embryos were isolated from the oviduct in Whitten’s
media with Hepes (Specialty media; Phillipsburg, NJ) con-
taining 0.05% hyaluronidase. Embryos were washed thor-
oughly in TE media and either removed for fixation or
allowed to develop in vitro at 37°C and 5% CO2. Oocytes
and embryos were fixed in 4% paraformaldehye in PBS for
20 min at room temperature. Following fixation, oocytes
and embryos were washed five times in PBS  1% BSA
(PBS/BSA) and then permeabilized with 0.5% Triton X-100
in PBS. Oocytes and embryos were then washed five times
in PBS/BSA and blocked for 30 min with PBS/BSA con-
taining 10% goat serum. Oocytes and embryos were then
incubated with 40 g/ml ePAD IgG or 40 g/ml guinea pig
IgG for 1 h at room temperature. Oocytes and embryos were
washed five times and incubated for 1 h at room temperature
with goat anti-guinea pig FITC-labeled secondary antibody
(Jackson ImmunoResearch). Oocytes/embryos were mounted
on slides and visualized under a Zeiss Standard 18 ultraviolet
microscope.
Confocal microscopy
Eggs and embryos used for confocal microscopy were
prepared as above except that in vivo derived embryos were
used. The morula and blastocyst staged embryos were ob-
tained by flushing the oviducts of mated females either 4 or
5 days following hCG injection and processed as above.
Microscopy images were obtained on a Ziess Axiovert 100
micro systems LSM confocal microscope. Each image was
acquired using 4 s scan averaged four times per line using a
40 oil lens with a zoom of approximately 2. False color
was added as appropriate.
Electron microscopy
Mouse ovaries were fixed for 2 h at room temperature in
8% paraformaldehyde buffered with 0.1 M sodium phos-
phate, pH 7.5. The ovaries were processed through a series
of ethanol washes to dehydration and embedded with Lowi-
cryl resin (Electron Microscopy Sciences, Fort Washington,
PA). Ultrathin sections were picked up on 75 mesh nickel
grids and immunolabeled with primary antibody overnight
at 4°C, washed, and secondary antibody on 5 nm colloidal
gold was added to sections at room temperature for 45 min,
washed, and heavy metal-stained with aqueous saturated
Uranyl acetate for 30 min. The sections were viewed and
photographed by using a JEOL 100CX2 electron micro-
scope.
Results
Tandem mass spectroscopic identification of ePAD, a
highly abundant novel egg protein
Zona-free mouse eggs (2850) were extracted, separated
on a 2D electrophoretic gel, and stained with Coomassie
(Fig. 1). Within a train of proteins (pI  5 to 5.5) two spots,
designated ePAD (Fig. 1, arrows) and migrating at 75
kDa, were cored from the gel, digested with trypsin, and
microsequenced by CAD Mass spectrometry. Twenty-eight
peptides were identified in the spot indicated by the arrow
on the left in Fig. 1, and 12 peptides were identified in the
spot indicated by the arrow on the right, with 5 common
peptides being shared between the 2 spots. The presence of
common peptides within the 2 spots suggested that the
entire protein train (Fig. 1, brackets) may arise from a single
gene or related genes. Comparison of the staining intensity
of this protein train with that of other protein spots found
that ePAD appears to be one of the most abundant proteins
in the ovulated mouse egg. When the identified peptides
were searched against nonredundant database sequences, it
was concluded that this protein had not been previously
characterized. One of the common peptides having the se-
quence CCLEEKVCGLLEPLGLK, however, matched 2
EST clones arising from 2-cell (AA645498) and 8-cell
(AU020751) mouse embryo cDNA libraries.
Cloning and characterization of ePAD
Repeated RACE PCR was performed by using an ovar-
ian Marathon-ready adapter-primed cDNA library and oli-
gonucleotide primers designed from the CCLEEKVCG-
LLEPLGLK peptide sequence, the matching EST clones, or
gene-specific sequences resulting from amplification of 5
and 3 PCR gene fragments. Oligonucleotides were de-
signed from the gene fragments and used to PCR-amplify a
2374-bp cDNA from the ovarian library. The gene was
inserted into a cloning vector and subsequent DNA se-
quencing revealed a contiguous open reading frame of 2043
bp which encoded a 681-amino-acid protein (Fig. 2). The
untranslated flanking regions are shown in lower case let-
ters. The GenBank Accession No. for this clone is
NP_694746. The computed mass and isoelectric point of the
deduced amino acid sequence is 76.7 and 5.36, respectively
(ExPASy compute pi/MW tool), which closely matched the
approximate mass and pI of the protein spots that were
cored from the gel for TMS analysis. Nineteen of the 28
peptides originally identified by TMS were found in the
deduced amino acid sequence and are underlined. When the
deduced ePAD amino acid sequence was searched against
the Prosite computational database, no highly significant
structural motifs were observed. An NCBI conserved do-
main search using the deduced amino acid sequence, how-
ever, identified a peptidylarginine deiminase (PAD) domain
(E value  0.0) that spanned the protein sequence from the
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seventh residue to the C terminus. Comparison of the se-
quence against the NCBI nonredundant database using the
BLAST algorithm found that the sequence was 96% iden-
tical to a recently submitted putative mouse PAD type
V-like protein sequence (XM_144067), which was pre-
dicted by NCBI’s automated sequence analysis program.
The next most similar sequence was a predicted human
putative human PAD type V-like protein sequence
(XP_017315.3) with an identity of 63%. ePAD was 40%
identical to all other characterized PAD sequences, includ-
ing those of mice, humans, rats, sheep, and chickens. A
direct comparison of ePAD with the four characterized
mouse PADs using the ClustalW alignment function in the
BioEdit sequence alignment editor indicated that ePAD is
approximately 40% identical to the known PADs, while
each of these PADs is approximately 50% identical to each
other (Fig. 3). Interestingly, most of the domains that are
conserved between the known PADs are also conserved in
ePAD, indicating that ePAD likely represents a new mem-
ber of the PAD enzyme family.
ePAD is expressed in oocytes and early cleavage-stage
embryos
An EST database search using the ePAD open reading
frame nucleotide sequence found nearly identical matches
in mouse ovary, unfertilized egg, fertilized egg, 2-cell em-
bryo, 8-cell embryo, and more recently, the day 0 neonatal
thymus (data not shown). This information led to the hy-
pothesis that ePAD may be an egg-abundant transcript
whose expression persists throughout the early stages of
cleavage. ePAD expression was examined in various tissues
by using Northern blotting, RT-PCR, and in situ hybridiza-
tion. A multitissue Northern blot (Clontech) containing 5
g poly(A) RNA, and a separate blot containing 40 g of
total ovarian RNA, were probed with a 32P-labeled random-
primed 1100 bp ePAD N-terminal DNA fragment. A single
2.4-kb message was found to be abundantly expressed in the
ovary (Fig. 4A). Subsequent multiple tissue Northern blot-
ting experiments using a single membrane showed similar
results (data not shown). Ovary-abundant expression of
ePAD was further confirmed by RT-PCR and Southern
blotting (Fig. 4B). A mouse multiple tissue cDNA panel
(Clontech) comprised of cDNA from 11 different tissues
(including day 7 and day 15 embryos) was used as template
in the PCRs. The oligonucleotide primers used for the PCRs
encompassed the ePAD ORF (2043 bp). A strong 2-kb
amplicon was detected in the ovary cDNA lane, a weaker
amplicon was seen in the testis cDNA lane, and no ampli-
cons were detected in lanes containing cDNA from other
tissues. To confirm the authenticity of the PCR amplicons
seen in the ovary and testis lanes, the PCR products were
blotted to a nitrocellulose membrane and the blot was
probed with the same 32P-labeled ePAD probe, which was
used for Northern blotting. Results showed that the PCR
products were derived from ePAD sequence (Fig 4B.). A
32P-labeled full-length -actin probe and olignulceotides
designed to amplify the open reading frame of G3PDH were
used as positive controls for the Northern blot and the
RT-PCR, respectively.
In situ hybridization experiments were then performed to
localize ePAD expression within the ovary. Results showed
ePAD message only in oocytes (Fig. 4C) and not in other
ovarian cell types. Further, ePAD message was not detected
in oviductal or testis cross sections (data not shown). Taken
together, these results suggest that ePAD is abundantly
expressed in the ovary (specifically within oocytes) and may
be expressed at lower levels in testis and thymus.
Fig. 4. Tissue distribution of ePAD. Northern blot analysis was performed on various tissues by using a P32-labeled 1100-bp ePAD DNA fragment (A). The
Northern membrane contained 40 g of total RNA for the ovary lane and 5 g poly (A) RNA for the other tissues (exposure time 24 h). ePAD was detected
as a single 2.4-kb band in the ovarian RNA lane. A -actin probe was used to control for RNA loading. RT-PCR and Southern blot analysis of ePAD tissue
distribution (B). Specific primers based on the ePAD open reading frame were used in PCRs to screen cDNA from various tissues for ePAD expression.
cDNA was tested from the following tissues: heart (Ht.), brain (Br), spleen (Sp), lung (Lu), Liver (Li), skeletal muscle (Sk), Kidney (Ki), testis (Te), day
7 embryo (d7), day 15 embryo (d15), and ovary (Ov). Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) primers were used as a positive control. A strong
ePAD amplicon was seen in the ovarian RNA lane, while a weak amplicon was seen in the testis lane. A Southern blot was performed by using a 32P-labeled
ePAD DNA fragment to confirm the authenticity of the amplicon. In situ hybridization of mouse ovarian tissue with ePAD anti-sense RNA (C) demonstrated
hybridizing to oocytes (white grains against dark field, indicated by arrows) but not to other ovarian cell types, while ePAD sense-strand RNA did not
specifically hybridize to any ovarian tissues. Testis and oviductal sections were also tested with the ePAD probes and no signal was detected (data not shown).
Fig. 5. A 75-kDa (pI 5.5) protein spot containing ePAD peptide sequence is specifically recognized by anti-ePAD antibodies. Antisera was generated in male
guinea pigs against a purified recombinant form of ePAD containing the N-terminal 200 amino acids. The preimmune sera was not reactive with either the
recombinant protein or with egg (50 mature zona-intact eggs per lane) or sperm proteins (1  106 per lane), while the anti-ePAD sera was reactive with
rePAD and with a 75-kDa egg protein, but not with sperm protein (A). The solubility characteristics of ePAD were investigated, and the protein was found
to partition with the 1% NP-10 soluble fraction (So.) and not with the insoluble fraction (In) under both reducing and nonreducing conditions (B). Three
hundred ovulated zona-intact mouse oocytes were extracted, separated by 2D electrophoresis, blotted to nitrocellulose, and egg proteins were resolved with
protogold. The blot was then probed with anti-ePAD preimmune IgG and prepared for protein detection by using enhanced chemiluminescence (ECL). The
blot was then washed and reprobed with anti-ePAD immune IgG. Arrows indicate reactive proteins at 75 and 110 kDa. Overlay image localizes reactive
proteins with protein spots resolved using protogold (C). This Western blot demonstrates that the anti-ePAD IgG strongly reacts with the protein train that
was originally cored for microsequence analysis. In a separate experiment, ePAD peptides were also found by TMS at 110 kDa (data not shown), which may
explain the observed upper reactive band (upper arrow).
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A 75-kDa (pI 5.5) protein spot which contains ePAD
peptide sequence is specifically recognized by anti-ePAD
antibodies generated against N-terminally truncated
recombinant ePAD
A cDNA encoding an N-terminal 200-amino-acid region
of ePAD was cloned into a bacterial expression vector,
expressed, purified, and used as an immunogen for anti-
ePAD antisera production in guinea pigs. The reactivity of
anti-ePAD antisera with the recombinant protein and with
the appropriately sized egg protein was first confirmed by
1D Western blotting. The preimmune sera was not reactive
with rePAD, egg, or sperm proteins. The immune sera was
reactive with rePAD and an appropriately sized egg protein;
however, the antibody did not react with sperm proteins
(Fig. 5A). Previous experiments had shown that ePAD was
soluble in several detergents (data not shown); this was
confirmed by probing Western blots of egg proteins ex-
tracted 1% NP-40 and separated under both reducing and
nonreducing conditions. As seen in Fig. 5B, ePAD is solu-
ble under both conditions. It is of interest that a higher MW
ePAD immunoreactive region appears under nonreducing
conditions, possibly indicating a protein–protein interaction.
Given that the anti-ePAD antisera appeared to be of high
quality, the IgG fraction of the preimmune and immune sera
was purified and used for all subsequent experiments.
On 2D immunoblots, the immune IgG to recombinant
ePAD reacted with an 75-kDa protein train at the precise
location from which the two spots were originally cored,
while the preimmune IgG was not reactive with any egg
proteins (Fig. 5C). This finding provided an immunological
proof that specific antibodies had been generated against the
original cored protein, and that the cDNA and amino acid
sequences obtained represented the intended spot. The train
of ePAD isoelectric variants at 75 kDa is likely indicative of
multiple posttranslational protein modifications. Lesser im-
munoreactivity was also noted with a protein train at 125
kDa and pI 5.5 (Fig. 5C, upper arrow). In order to determine
whether this immunoreactivity at 125 kDa represented au-
thentic ePAD, bands in the 125-kDa MW range were mi-
crosequenced from a 1D gel, and ePAD peptide sequences
were noted, confirming that the band at 125 kDa in Fig. 5C
represents a higher molecular weight form of ePAD (data
not shown).
Ontogenic expression and subcellular localization of
ePAD
The monospecific IgG to rec ePAD was employed to
investigate the developmental expression of ePAD. Ovaries
were collected from 2, 4, 8, and 15 wk females, as well as
from retired breeders and either embedded for sectioning
and indirect immunofluorescence or proteins were extracted
for Western blotting with equal concentrations of ovarian
protein extract loaded in each lane. By Western blot (Fig.
6A), the ePAD protein was found at all stages examined.
ePAD’s relative abundance, however, appeared to be high-
est at 2 weeks of development (the earliest stage tested) and
to gradually decrease as the mice aged. Since oocyte num-
bers are reduced over time through ovulation and atresia,
and since ovarian structures such as corpora lutea and in-
terstitial glands differentiate and regress, the ratio of oocytes
to total ovarian tissue mass might be expected to vary at
some stages. To control for this possibility, the blots were
stripped and reprobed with antibodies to ZP3. Results
showed that, as opposed to ePAD, the expression levels of
this oocyte-specific protein appeared to remain constant or
possibly increase as the ovaries developed and aged. There-
fore, the observed decreases at 15 weeks and in retired
breeders are unlikely to be the result of unequal numbers of
oocytes represented in each sample.
Indirect immunofluorescence of the ovarian cryostat sec-
tions confirmed that ePAD was expressed in an oocyte-
specific manner in all types of follicles and in all develop-
mental stages tested (Fig 6B, stages other than 2 week and
retired breeders are not shown). In 2-week-old females,
abundant oocyte staining was observed in many primordial
follicles (Pm.) and in all primary follicles (Pr.). When ovar-
ian sections of mature females were stained with the anti-
ePAD IgG, intense staining was observed in oocytes within
primary, secondary (Sec.), and some primordial follicles.
Staining was also observed in tertiary (Graafian) follicles
Fig. 6. Ontogenic expression of ePAD. Ovaries were collected from mice at different stages of development and either extracted for Western blot analysis
(A) or prepared for indirect immunofluorescence (B). (A) Prior to Western blot analysis, blots were probed with Ponceu to control for protein loading. When
blots of ovarian extracts were probed with anti-ePAD IgG, ePAD expression appeared highest in 2-week-old females and then declined slightly during animal
growth. The blots were then stripped and reprobed with anti-ZP3 IgG in order to compare ePAD expression with that of another oocyte-specific protein. As
opposed to ePAD, ZP3 expression appeared to increase slightly during animal growth. (B) Ovarian cross-sections from 2-week-old females and mature
females were probed with anti-ePAD IgG and prepared for indirect immunofluorescence imaging (IIF) and phase contrast microscopy. ePAD expression in
2-week-old females was observed in eggs contained within primordial (Pm.) and primary follicles (Pr.). In mature ovaries, ePAD expression is seen in primary
and secondary (Sec.) oocytes, while other ovarian tissues were not stained. Oocytes contained within tertiary follicles were also recognized by anti-ePAD
IgG (Data not shown). These results further confirm the oocyte-abundant expression pattern of ePAD.
Fig. 7. Developmental expression of ePAD in the oocyte and early embryo. Indirect immunofluorescence (IIF) and Western blot (WB) analysis were
performed to determine whether ePAD continues to be expressed in the developing embryo. Immature (GV), mature (MII), and pronuclear (PN)
oocytes/embryos were collected from females, while 2-cell, 4-cell, morula (Mo.), and blastocyst (Bl.) were collected following culture from the pronuclear
stage. Indirect immunofluorescence was the performed on the eggs/embryos by using either ePAD preimmune IgG (PI, negative control, MII eggs) or immune
IgG. Western blotting (WB) was also performed on each of the stages shown using 20 oocytes/embryos per group. ePAD appears to be expressed at all stages
shown, with a decrease in expression levels being observed at the blastocyst stage.
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(data not shown). No ovarian cell types other than the
oocytes were reactive with the antibody.
The expression of ePAD protein during oocyte matura-
tion, fertilization, and early embryonic development was
next investigated. Immature germinal vesicle-stage oocytes
(GV), mature metaphase II arrested eggs (MII), and pro-
nuclear zygotes (PN) were collected from females and im-
mediately fixed. Pronuclear-stage embryos were also col-
lected and cultured in vitro, and the cultured embryos were
harvested at the 2-cell, 4-cell, morula (Mo.), and blastocyst
(Bl.) stage and fixed for immunocytochemistry. All stages
were then permeablized, stained with secondary antibody
alone, anti-ePAD preimmune IgG, or anti ePAD immune
IgG, and analyzed by indirect immunofluorescence. No
staining was observed when eggs were stained with anti-
ePAD preimmune IgG (Fig. 7, PI). Further, neither the
anti-ePAD preimmune IgG or the secondary antibody alone
stained any of the other stages tested (data not shown).
Anti-ePAD immune IgG immunofluorescence staining in-
dicated that ePAD protein was present at all stages, with a
more heterogeneous staining pattern seen among the blas-
tomeres at the morula stage and an apparent decrease in
staining intensity seen at the blastocyst stage (Fig. 7). To
test whether the ePAD protein detected by microscopic
methods could be confirmed biochemically, 20 eggs/em-
bryos were collected for each stage as described, extracted,
and blotted to a nitrocellulose membrane. The blot, probed
with anti-ePAD antibody, confirmed that ePAD was present
until the blastocyst stage, at which point ePAD expression
decreased (Fig. 7, WB).
Confocal analysis was then performed to further inves-
tigate the subcellular localization of ePAD (Fig. 8). Evalu-
ation of immature oocyte (GV) cross sections showed that
ePAD localized predominantly to the cortical region of the
oocyte, with decreased staining in interior cytoplasmic re-
gions. Low levels of ePAD staining were noted in the
oocyte nucleus, with complete exclusion of staining from
the nucleolus. Close examination of the oocyte cytoplasm
revealed that ePAD staining was punctate in nature. This
pattern of punctate staining suggested that ePAD might be
associated with a specific cytoplasmic element. In fertilized
eggs (Fert.), ePAD was expressed in punctate patches
throughout the cytoplasm. In the morula and blastocyst
(Blast.), ePAD appeared to localize mainly to the cyto-
plasm; however, a limited amount of nuclear staining was
noted in some blastomeres. Note that the blastomere indi-
cated by the arrow (Fig. 8) appeared to be in metaphase and
that ePAD was excluded from chromatin-containing re-
gions. Intense cortical immunofluorescent staining was seen
at each of the developmental stages shown, except in the
morula, in which cortical staining was limited to the exter-
nal surface of the blastomeres and appeared polarized. In the
blastocyst, the cortical staining was mainly limited to the
cells of the trophectoderm (Fig. 8).
To investigate ePAD localization at the ultrastructural
level, immunoelectron microscopy was performed by using
Fig. 8. Scanning confocal analysis of ePAD subcellular localization. Immature oocytes (GV) were collected from ovaries. For fertilized eggs (Fert.),
metaphase II eggs were collected from superovulated females, the zona pellucidi were removed with chymotrypsin, and the eggs were coincubated with sperm
for 45 min and fixed for evaluation. Morula and blastocysts were collected directly from females either 4 or 5 days after mating. In immature oocytes, ePAD
appears to be predominantly expressed in the cytoplasm; however, some nuclear staining is also evident, while no staining is seen in the nucleolus. In fertilized
eggs, ePAD is expressed in punctate patches the throughout the cytoplasm. In the morula and blastocyst (Blast.), ePAD appears to be localized mainly to
the cytoplasm; however, there does appear to be a limited amount of nuclear staining in some blastomeres. Note that the blastomere indicated by the arrow
appears to be in metaphase and that ePAD is excluded from the chromatin-containing region. Also, cortical staining is seen at each of the developmental stages
shown. In the morula, however, the cortical staining is limited to the external surface of the blastomeres and appears polarized. In the blastocyst, the cortical
staining is mainly limited to the trophectoderm. IIF, indirect immunofluorescence; Ph., phase contrast.
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anti-ePAD-coated 10-nm gold particles to probe ovarian
and cumulus–oocyte complex cross-sections (Fig. 9). Com-
parison of low magnification fields revealed that the preim-
mune IgG-coated gold particles did not bind to the egg
cytoplasm, while the anti-ePAD IgG gold particles localized
within the egg cytoplasm to whorls of electron dense ma-
terial. Anti-ePAD immunogold particles were not found to
specifically associate with any other ovarian cell type in-
Fig. 9. Immunoelectron microscopic localization of ePAD in oocytes. At low magnification (LM) using 10-mm-labeled gold particles, few preimmune-coated
(PI) particles are seen in a cytoplasmic section of an egg, while immune-coated particles (I) are found to be abundantly associated with the egg cytoplasm
in a swirling pattern. Higher magnification (HM) using 5-mm gold particles reveals few preimmune particles in the cytoplasmic region of the egg, while
numerous immune particles predominantly localize to the cytoplasmic sheets of the egg. At high magnification, 10-mm particles coated with anti-ePAD IgG
clearly localize to the sheets. This cytoskeletal structure is unique to the mammalian egg and embryo and is thought to be mainly composed of intermediate
filaments.
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vestigated, nor did the particles appear to specifically asso-
ciate with electron lucent regions of cytoplasm. At higher
magnifications, anti-ePAD immunogold particles localized
to multilamellar filamentous cytoskeletal structures that
have been previously named cytoplasmic sheets. These cy-
toskeletal specializations are distinctive in their lamellar
appearance within the cytoplasm of the egg and early em-
bryo (Capco et al., 1993).
Discussion
Our laboratory has been utilizing proteomics to charac-
terize proteins in the mouse egg in an effort to identify new
potential contraceptive targets. We chose to clone and char-
acterize ePAD based on the observation that it represented
one of the most abundant proteins yet to be characterized in
the mouse egg. The specific localization of ePAD to oocytes
in ovarian sections and its homology to a well-characterized
enzyme family that has known in vitro and in vivo sub-
strates supports further development of small molecule in-
hibitors to this contraceptive target.
A central question germane to the potential role of ePAD
in egg physiology is whether ePAD functions as an egg
and/or embryo peptidylarginine deiminase, and if so, what
are its substrates? Previous experiments have shown that the
cytoplasmic sheets consist of a highly cross-linked network
of Triton X-100 detergent-insoluble intermediate filaments
that are coated with a Tween 20 detergent-soluble protein
component. The most abundant soluble component of the
sheets is an 69-kDa protein that has not been character-
ized at the molecular level (Gallicano et al., 1994a). Given
ePADs localization to the cytoskeletal sheets, its solubility
characteristics, and its molecular weight (75 vs 69 kDa), it
is tempting to speculate that ePAD is the soluble 69-kDa
protein previously described in the literature (Gallicano et
al., 1994a). The molecular nature of the insoluble compo-
nent has been partially characterized and shown to contain
cytokeratin (Gallicano et al., 1994a). Because keratin is
such a well-characterized PAD substrate in epithelial cells
(Senshu et al., 1999a,b), it represents an obvious potential
substrate for ePAD in eggs and embryos.
In epithelial cells, deimination of specific arginine resi-
dues in keratin and filaggrin is known to be involved in the
conversion of a preexisting fine cytokeratin network to more
densely bundled linear filamentous structures (Ishida-
Yamamoto et al., 2002). This reorganization is reminiscent
of changes that have been described in the cytoskeletal
sheets in the egg where the preexisting multilamellar,
whorl-like pattern in unfertilized eggs (similar to that seen
in Fig. 9) becomes more linearly arranged in the fertilized
zygote (Gallicano et al., 1995). At compaction, the sheets
appear as highly polarized structures with one end anchored
on the apical plasma membrane and extending downward
toward the basolateral surface within each blastomere. As
with ePAD protein expression, by the blastocyst stage of
development, the sheet density begins to diminish. In the
trophectoderm, the sheets are localized near the plasma
lamina, while in the inner cell mass blastomeres, the sheets
tend to be more centrally located (Capco et al., 1993).
Because PADs are calcium-dependent enzymes, fertili-
zation represents a particularly interesting developmental
stage for potential ePAD activity since large calcium tran-
sients are known to occur following sperm–egg fusion (Car-
roll, 2001). Following fertilization, one could imagine that
the calcium transients could activate ePAD, which would
then deiminate keratin, resulting in the observed cytoskel-
etal sheet reorganization. Such reorganization may be es-
sential for sperm internalization or polar body extrusion.
In addition to the keratins of the cytoskeletal sheets, the
nuclear localization of ePAD suggests that other proteins
also represent potential ePAD deimination targets at fertil-
ization. For example, protamine, an arginine-rich (60%
arginine residues) sperm-specific histone-like protein, is
known to be an excellent in vitro substrate for PADs (Sug-
awara et al., 1982). Given that substrate deimination causes
changes in secondary structure (Tarcsa et al., 1996), deimi-
nation of sperm protamine by ePAD, following gamete
fusion, might facilitate nuclear decondensation. In fact, we
have found that commercially available skeletal muscle
PAD readily decondenses sperm chromatin in vitro (data
not shown). Further experiments are being performed to
determine whether either native or full-length recombinaint
ePAD can decondense sperm in vitro and in vivo.
Histone proteins in HL-60 granulocytes have recently
been found to contain citrulline residues and therefore are
likely substrates for PADs (Hagiwara et al., 2002). The
investigators who made this observation hypothesized that
the N-terminal tails represent the most likely site for PAD
activity, and if this prediction is correct, deimination of the
histone tails represents a novel posttranslational histone
modification. Other N-terminal histone modifications, such
as acetylation, phosphorylation, and methylation, have been
shown to alter chromatin structure and thus lead to changes
in transcriptional activity of specific genes (Jenuwein and
Allis, 2001). It is well documented that there is a dramatic
reprogramming of gene expression patterns following fer-
tilization and prior to zygotic gene activation; however, the
mechanism by which the egg is able to perform this remark-
able task is unknown. The egg factors involved in this
process are likely to be cytoplasmic, as demonstrated by the
observation that somatic cell reprogramming requires that
the nuclei be placed in the context of the egg cytoplasm
(Surani, 2001). It will be of interest to establish whether
ePAD can deiminate egg/embryo histones and thus possibly
play a role in the reprogramming process.
To conclude, we have cloned and characterized ePAD, a
highly abundant egg and embryo protein that is 40%
identical to the peptidylarginine deiminase enzyme family.
ePAD appears to be expressed from the primary oocyte
stage of oogenesis until at least the blastocyst stage of
development. At the ultrastructural level, ePAD localizes to
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the egg cytoplasmic sheets, keratin-containing structures
known to undergo changes in their structure during early
development. As one of the most abundant proteins in the
egg proteome, further consideration of the functions of this
potentially novel deiminase are germane to fertilization and
early development.
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